anonymous
Guest
anonymous
Guest
You have inside info? Yeah right. This company is notorious for spring or holiday layoffs. We made it for now, layoffs probably coming this winter.
Well the email that just came out might change things. Generic Entresto here we come. I don’t believe their lies, they are losing the battle and don’t want to face the music.You have inside info? Yeah right. This company is notorious for spring or holiday layoffs. We made it for now, layoffs probably coming this winter.
Well the email that just came out might change things. Generic Entresto here we come. I don’t believe their lies, they are losing the battle and don’t want to face the music.
From what I’ve heard they want to keep customer relationships intact as much as possible, and changes will happen in the 3rd or 4th q.
The ships is sinking and they keep telling us to sell and close. No leadership, no honesty, no clue.Well the email that just came out might change things. Generic Entresto here we come. I don’t believe their lies, they are losing the battle and don’t want to face the music.
It should, let's be honest here half of us don't have anything to do! The ABLs are worse, they don't do anything productive and cost twice as much as a rep!
The only guarantees are that it will be handled poorly, unprofessionally and without a shred of concern for the impacted parties.
Instead of showing a modicum of decency and being transparent, you'll be fed a steady diet of lies, (like yesterday's e-mail from Miller), lazy bromides (think of the patients we serve!), and tone-deaf company cheerleading (Novartis has an amazing future!).
You all have seen it before, but judging by what we have seen from Dez, this will be a particularly ugly process.
Yeah, I was late getting on, but I’m sure I didn’t miss anything. Did they even mention the possibility of a reorg, which is of course the elephant in the room? I’m guessing no mention.Well said, even though I had to look up a couple of the words. That is exactly what today's Entresto call felt like.
Yeah, I was late getting on, but I’m sure I didn’t miss anything. Did they even mention the possibility of a reorg, which is of course the elephant in the room? I’m guessing no mention.
drink from my bowelsYou are a liar and cannot be trusted
Exactly. They are worthless.The first ten to go should be from the dsa team. They are worthless.
Realistically it should be closer to 250 remaining. Leqvio Leads have too small of a territory currently. They all have crappy target lists full of HCPs that they either can’t see or are not worth seeing. The better option would be to double the size of their geographies and have a more robust list of providers to get business from.We all know our division could be cut by 75% without Entresto. Pucker up. It's coming. There will be less than 500 of us left in CV by Vegas.
No doubtRealistically it should be closer to 250 remaining. Leqvio Leads have too small of a territory currently. They all have crappy target lists full of HCPs that they either can’t see or are not worth seeing. The better option would be to double the size of their geographies and have a more robust list of providers to get business from.
A better plan would be to throw the target lists out the window and use PRISM to determine who is using Repatha to call on those providers, in places where we can make a difference. My Novartis mandated targeting does not line up with use. If Novartis would just get out of my way and pay me for success, I could do a better job.Realistically it should be closer to 250 remaining. Leqvio Leads have too small of a territory currently. They all have crappy target lists full of HCPs that they either can’t see or are not worth seeing. The better option would be to double the size of their geographies and have a more robust list of providers to get business from.
You can double the size of my territory and I wouldn’t even blink. In fact, I would welcome it. It would give me more to do.Realistically it should be closer to 250 remaining. Leqvio Leads have too small of a territory currently. They all have crappy target lists full of HCPs that they either can’t see or are not worth seeing. The better option would be to double the size of their geographies and have a more robust list of providers to get business from.
"use PRISM".A better plan would be to throw the target lists out the window and use PRISM to determine who is using Repatha to call on those providers, in places where we can make a difference. My Novartis mandated targeting does not line up with use. If Novartis would just get out of my way and pay me for success, I could do a better job.